Aduro BioTech is a clinical-stage company that focuses on developing technology platforms to stimulate immune responses against cancer. The company's lead product candidate, CRS-207, is currently in Phase IIb clinical trials for the treatment of pancreatic cancer and malignant pleural mesothelioma. Aduro BioTech is dedicated to advancing immuno-oncology treatments with the goal of providing effective and durable therapies for cancer patients.
Aduro BioTech Inc's ticker is ADRO
The company's shares trade on the NASDAQ stock exchange
They are based in Berkeley, California
There are 51-200 employees working at Aduro BioTech Inc
It is http://www.aduro.com/
Aduro BioTech Inc is in the Healthcare sector
Aduro BioTech Inc is in the Biotechnology industry
The following five companies are Aduro BioTech Inc's industry peers: